Indofarma Tbk Stock EBITDA
| INAF Stock | IDR 126.00 0.00 0.00% |
Indofarma Tbk fundamentals help investors to digest information that contributes to Indofarma Tbk's financial success or failures. It also enables traders to predict the movement of Indofarma Stock. The fundamental analysis module provides a way to measure Indofarma Tbk's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Indofarma Tbk stock.
Indofarma |
Indofarma Tbk Company EBITDA Analysis
Indofarma Tbk's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Indofarma Tbk EBITDA | 70.22 B |
Most of Indofarma Tbk's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Indofarma Tbk is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
According to the company disclosure, Indofarma Tbk reported earnings before interest,tax, depreciation and amortization of 70.22 B. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The ebitda for all Indonesia stocks is notably lower than that of the firm.
Indofarma EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Indofarma Tbk's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Indofarma Tbk could also be used in its relative valuation, which is a method of valuing Indofarma Tbk by comparing valuation metrics of similar companies.Indofarma Tbk is currently under evaluation in ebitda category among its peers.
Indofarma Fundamentals
| Return On Equity | -0.59 | |||
| Return On Asset | -0.0451 | |||
| Profit Margin | (0.1) % | |||
| Operating Margin | (0.06) % | |||
| Current Valuation | 3.17 T | |||
| Shares Outstanding | 3.1 B | |||
| Shares Owned By Insiders | 88.00 % | |||
| Price To Book | 8.91 X | |||
| Price To Sales | 1.25 X | |||
| Revenue | 2.9 T | |||
| Gross Profit | 442.87 B | |||
| EBITDA | 70.22 B | |||
| Net Income | (37.58 B) | |||
| Total Debt | 397.52 B | |||
| Book Value Per Share | 104.92 X | |||
| Cash Flow From Operations | 92.9 B | |||
| Earnings Per Share | (29.18) X | |||
| Number Of Employees | 1.18 K | |||
| Beta | -0.22 | |||
| Market Capitalization | 2.59 T | |||
| Total Asset | 2.01 T | |||
| Z Score | 4.6 | |||
| Net Asset | 2.01 T |
About Indofarma Tbk Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Indofarma Tbk's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Indofarma Tbk using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Indofarma Tbk based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Indofarma Stock
Indofarma Tbk financial ratios help investors to determine whether Indofarma Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Indofarma with respect to the benefits of owning Indofarma Tbk security.